NEW YORK, May 4, 2015 /PRNewswire/ -- Harwood Feffer LLP
(www.hfesq.com) is investigating potential claims against the board
of directors of Cellular Biomedicine Group, Inc. ("CBMG" or the
"Company") (NASDAQ: CBMG), concerning whether the board has
breached its fiduciary duties to shareholders.
On April 7, 2015, an article was
posted on SeekingAlpha.com reporting that CBMG has engaged
in a scheme to defrau investors. According to the article,
CBMG used undisclosed paid stock promoters and the Company's
financial statements suffered from "multiple accounting and
financial integrity issues" including material weaknesses to
internal controls.
Our investigation concerns whether the Company board of
directors has breached its fiduciary duties to shareholders,
grossly mismanaged the Company, and/or committed abuses of control
in connection with the foregoing.
If you own CBMG shares and wish to discuss this matter with us,
or have any questions concerning your rights and interests with
regard to this matter, please contact:
Robert I. Harwood, Esq.
Benjamin I. Sachs-Michaels, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
(212)935-7400
Email: bsachsmichaels@hfesq.com
Website: http://www.hfesq.com
Follow us on Twitter: @HarwoodFeffer
Harwood Feffer has been
representing individual and institutional investors for many years,
serving as lead counsel in numerous cases in federal and state
courts. Please visit the Harwood Feffer LLP website
(http://www.hfesq.com) for more information about the
firm.
The law firm responsible for this advertisement is Harwood
Feffer LLP (www.hfesq.com). Prior results do not guarantee or
predict a similar outcome with respect to any future matter.
Logo -
http://photos.prnewswire.com/prnh/20120215/MM54604LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/harwood-feffer-llp-announces-investigation-of-cellular-biomedicine-group-inc-300076898.html
SOURCE Harwood Feffer LLP